Now Available: Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2012

2012-03-08 07:15:21 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2012

Summary

Global Markets Direct's, 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2012', provides an overview of the Type 1 Diabetes (Juvenile Diabetes) therapeutic pipeline. This report provides information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with latest updates, and special features on late-stage and discontinued projects.

It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes). 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/335209_type_1_diabetes_juvenile_diabetes_pip ..


Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Type 1 Diabetes (Juvenile Diabetes).
* A review of the Type 1 Diabetes (Juvenile Diabetes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Type 1 Diabetes (Juvenile Diabetes) pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Type 1 Diabetes (Juvenile Diabetes).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Type 1 Diabetes (Juvenile Diabetes) pipeline depth and focus of Type 1 Diabetes (Juvenile Diabetes) therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 1 Diabetes (Juvenile Diabetes) Overview
Therapeutics Development
An Overview of Pipeline Products for Type 1 Diabetes (Juvenile Diabetes)
Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Products under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Type 1 Diabetes (Juvenile Diabetes) Therapeutics Development
Osiris Therapeutics, Inc.
Sanofi-Aventis
Eli Lilly and Company
Inovio Biomedical Corporation
MedImmune LLC
Taisho Pharmaceutical Co., Ltd.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Novartis AG
Biocon Limited
Hadasit Medical Research Services & Development Ltd
AutoImmune Inc.
Biodel Inc.
Geron Corporation
MannKind Corporation
Halozyme Therapeutics
4SC AG
Evotec Aktiengesellschaft
Living Cell Technologies Limited
Oramed Pharmaceuticals, Inc.
MAP Pharmaceuticals, Inc.
Flamel Technologies S.A.
Tolerx, Inc.
XOMA Ltd.
Lipoxen PLC
SemBiosys Genetics Inc.
Uni-Bio Science Group Ltd.
Kamada Ltd.
DiaMedica Inc.
Affimed Therapeutics AG
Axxam SpA
ActogeniX NV
Bayhill Therapeutics, Inc.
Phosphagenics Limited
Artielle ImmunoTherapeutics, Inc.
MacroGenics, Inc.
ApoImmune, Inc.
DiaKine Therapeutics, Inc.
Peptimmune, Inc.
Kineta, Inc.
Creative Peptides Sweden AB
Andromeda Biotech Ltd.
AIM Therapeutics Inc.
NovImmune SA
Txcell SA
TcL Pharma SAS
Versartis, Inc.
Virobay Inc.
Fate Therapeutics, Inc.
Immunomod, LLC
Immunocore Limited.
Novocell, Inc.
Exsulin Corporation
NasVax Ltd.
REGiMMUNE Corporation
Adocia
Diasome Pharmaceuticals, Inc.
Cebix Incorporated

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=335209&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.